Home›Screener›NRIX›Profile
D
39/100

Nurix Therapeutics

NRIXProtein Degradation
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Nurix Therapeutics (NRIX) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 4 Phase 1[2].

NRIX has 1 Form 4 insider filing recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001549595 (2026-04-11) ↗
🔬
Clinical Trials
5
NCT04830137Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06717269Healthy Volunteer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
1 filing
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Protein Degradation)
GLUEMonte Rosa Therapeutics
D
KYMRKymera Therapeutics
D
ARVNArvinas Inc
F
Data Provenance
cik1 verified
clinical trial5 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR